Lawsuit Claims Montana Is Not Enforcing Strict Asbestos Laws

A prominent, family-run asbestos-disposal company is suing the Montana Department of Environmental Quality (DEQ) for failing to enforce the state’s strict asbestos-waste laws. Doug Ingraham, corporate secretary at Ingraham Environmental Inc., believes the DEQ has been delinquent in its duty to protect citizens from unnecessary asbestos exposure. “It’s a simple case of the government maintaining the status quo and the public feeling protected, when actually, the government is failing them,” Ingraham told Ingraham said the DEQ has failed to apply the laws regarding asbestos abatement and disposal, allowing too much unregulated dumping at landfills across the state. Exposure to asbestos can lead to a number of serious health issues, including asbestosis, lung cancer and mesothelioma. Dump-Site Workers at Risk for Exposure The legal filings by Ingraham are designed to push the DEQ toward tougher enforcement of the current laws. The lawsuit was filed in the district court of Butte-Silver Bow County and assigned to Judge Brad Newman. “Asbestos waste is regularly being dumped in open air in our landfills, endangering landfill workers, transporters and anyone who breathes air in the area of these dumps,” notes Ingraham’s legal petition. The DEQ countered with its own petition that says the responsibility for compliance is on the landfill operators and the owners of the buildings being demolished or abated. The agency also says ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: asbestos abatement asbestos cleanup in libby montana asbestos landfill workers Asbestos laws in Montana asbestos lawsuit montana asbestos mines montana asbestos-disposal companies Butte-Silver Bow County DEQ Montana Doug Ingraham Ingra Source Type: news

Related Links:

CONCLUSION: In this contest, MacroH2A.1 overexpression supports its function as an epigenetic stabilizer that helps to establish and maintain differentiated states. PMID: 32077824 [PubMed - as supplied by publisher]
Source: Current Molecular Medicine - Category: Molecular Biology Authors: Tags: Curr Mol Med Source Type: research
Cellular Analytics, a biotechnology company in Ontario, Canada, has unveiled a novel liquid biopsy test for mesothelioma that could lead to more effective management of this rare cancer. The test has the potential to produce a much-earlier diagnosis of disease and the ability to personalize treatment and better predict a patient’s response to specific therapies. “We could change completely how this disease is viewed,” Dr. Brent Zanke, a specialist in diagnostic oncology and chief executive officer of Cellular Analytics, told The Mesothelioma Center at “It’s a proactive way to get...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor originating from mesothelial cells. It is associated with exposure to asbestos, mainly occupational, rarely environmental or domestic. Diagnosis is usually made at an advanced stage because symptoms are non-specific and late. The management of this tumor is challenging and outcome is poor. Therapeutic strategies are mainly based on surgery with curative intent or palliative cytotoxic chemotherapy. Few patients are candidates for surgery which must necessarily take into account numerous factors (i.e.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Malignant pleural mesothelioma (MPM) is highly aggressive neoplasm, with a median survival of
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
The U.S. Food and Drug Administration has granted final approval of Pemfexy, a new brand of the chemotherapy drug pemetrexed, to combat malignant mesothelioma and advanced stage non-small cell lung cancer. The approval will allow oncologists to offer an alternative to Alimta, which today is considered standard pemetrexed and manufactured by Eli Lilly and Company. The chemotherapy drug is designed to block DNA replication and cell division. However, Pemfexy will not be available until February 2022. The FDA approval is limited to pleural mesothelioma patients whose disease is unresectable. Pemfexy is produced by Eagle Pharm...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The U.S. Food and Drug Administration moved closer on Tuesday to formulating standardized testing of talc-based products for the presence of toxic asbestos fibers. Experts from eight different federal agencies explained earlier recommendations at a day-long hearing. The session also featured input from 25 members of the public, which included industry representatives, consumer advocates and testing experts. “Standards are needed,” said Dr. Paul Howard, FDA Office of Regulatory Science, during his presentation. “They just don’t exist at this time.” Dr. Linda Katz, director of the FDA Office of ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Background: Pemetrexed is an antifolate cytostatic drug that targets multiple enzymes involved in folate biosynthesis and is indicated for treatment of non–small-cell lung cancer and malignant pleural mesothelioma. As evidence for an exposure–response/toxicity relationship is accumulating, dose individualization using therapeutic drug monitoring may be a feasible strategy to optimize treatment. The purpose of this study was to develop a simple, sensitive, high-performance liquid chromatography method with UV detection for quantification of pemetrexed levels in human plasma. Method: The method involves a si...
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Short Communication Source Type: research
Publication date: Available online 10 January 2020Source: Pathology - Research and PracticeAuthor(s): Masanori Matsuda, Hironori Ninomiya, Ryo Wakejima, Kentaro Inamura, Sakae Okumura, Mingyon Mun, Masanobu Kitagawa, Yuichi IshikawaAbstractCalretinin, a mesothelioma marker, is sometimes expressed in lung cancer, which may complicate the differential diagnosis of mesothelioma. Here, the clinicopathological and immunohistochemical characteristics of calretinin-positive lung cancer were examined to reduce confusion with malignant mesothelioma. Calretinin expression in 307 consecutive cases of lung cancer was evaluated immunoh...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
A patient diagnosed with pleural and peritoneal mesothelioma today can survive well beyond expectations, provided personalized treatment can be found at a specialty center. Research from the Columbia University Medical Center in New York City has shown that despite the poor prognosis typically accompanies this rare diagnosis, patients still can thrive. “This is an understudied, and poorly understood, group of patients that often is just written off,” surgical oncologist Dr. Michael Kluger at Columbia told The Mesothelioma Center at “But we’ve shown a meaningful survival.” Kluger,...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Source: Critical Reviews in Toxicology - Category: Toxicology Authors: Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Environmental Health | Government | Lawsuits | Legislation | Lung Cancer | Mesothelioma | Small Businesses | USA Health